Initial $50M Series A investment from founding investor RTW Investments Proceeds will fund clinical development of PRO-203 in systemic sclerosis (SSc) and multiple additional severe autoimmune diseases March 03, 2026 -- Prolium Bioscience, Inc. (Prolium), a clinical stage biotechnology company, today announced its launch with a $50 million Series A Financing to develop PRO-203, a potential best-in-class CD20xCD3 T-cell engager, for severe autoimmune disease. The financing was led by its foundin

A late-stage Chinese biotech in one of the hottest areas of drug development has corralled 500 million Chinese yuan (about $72 million) in a Series C from OrbiMed, Qiming Venture Partners and other investors, according to an announcement on WeChat. The Beijing-based startup, called QL Biopharm, collected the Series C as its Phase 3 obesity trial kicks into gear. In January, QL dosed the first patient in a China-based study of zovaglutide, or ZT002, its once-monthly GLP-1 receptor agonist inject

Feb. 24, 2026 -- Turbine, a leading virtual biology company, today announced a $25 million Series B financing, an expansion of its virtual cell platform across industries and a new immunology-focused partnership with a top 10 pharma company. The Series B round is led by Interactive Venture Partners, with participation from Beiersdorf AG and existing investors, including MSD Global Health Innovation, Accel and Mercia. "Central and Eastern Europe has produced exceptional innovation, and Turbine

Feb. 25, 2026 -- Abram Scientific, a medical device company focused on advancing next-generation coagulation diagnostics, today announced the closing of a $11.75 million Series A financing round. The round was led by global pharmaceutical leader Octapharma AG, with additional participation from existing and new investors affiliated with University of Colorado Anschutz. This funding will accelerate the development of Abram Scientific's proprietary portable platform, CoagCare™, for aiding the eva

February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 6 million to Basilea to continue the development of Basilea’s novel

Ontario's FAST program aims to speed up access to breakthrough cancer drugs for patients by almost a full year sooner.1 Itovebi offers a targeted treatment for advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation, following recurrence on or after completing adjuvant endocrine treatment. This mutation is found in approximately 40 per cent of HR-positive breast cancers and is generally associated with poor outcomes.2,3,4 Feb. 24, 2026 - Hoffmann-La Roche Limited (Roche Canada

Gilead Sciences has struck a deal to buy Arcellx for $7.8 billion to take full control of a CAR-T cell therapy that is on the cusp of approval. Arcellx partnered with Gilead to develop the BCMA-directed CAR-T anitocabtagene autoleucel (anito-cel) in 2022. Gilead invested in Arcellx as part of the agreement and, having invested again when amending the deal in 2023, owns 11.5% of the company. With Gilead on the hook for $530 million in milestones for anito-cel, analysts had speculated about a pot

Feb. 20, 2026 -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered into a definitive agreement for a strategic private placement of $1 million. The financing was structured to reflect the company's current operational momentum and the underlying value of its NurOwn® platform. Premium Pricing: The common stock was priced at $0.60 per share, representing a significant premium to the $0.

Feb. 17, 2026 -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced that it, together with leading glioblastoma researchers at KU Leuven, has been awarded a EUR 2.5 million grant by the European Innovation Council (EIC) to advance a precision immune therapy for glioblastoma, the most common and aggressive brain tumour which currently lacks effective treatment. In the project GLIOBREAK, Beactica and KU Leuven are joining forces to advance BEA-17, Beactica's wholly ow

Newron Pharmaceuticals S.p.A. (“Newron”, or the “Company”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it has entered into an agreement for the subscription of newly issued shares for proceeds of up to EUR 38 million with a group of existing and new shareholders from Europe and Asia, strengthening the Company’s financial position as it advances the